Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
06 March 2023 - 11:39AM
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company
transforming the discovery and development of antibody-based
therapies, today announced the appointment of Professor Aurélien
Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board
(the “SAB”). Professor Marabelle is a physician-scientist with
expertise in oncology and immunology. His clinical practice is
dedicated to early phase clinical trials of cancer immunotherapies
with strong translational evidence within the Drug Development
Department (DITEP) of Gustave Roussy Cancer Center in France. He
leads a translational research laboratory (LRTI) within the INSERM
U1015 with a focus on mechanisms of action of immune targeted
therapies.
Professor Marabelle commented, “As CTLA-4 is upregulated on the
membrane of regulatory T-cells (Tregs) upon T-cell receptor
engagement, it is therefore an opportunity to target and deplete
tumor-specific Tregs specifically within the tumor microenvironment
(TME) for this proven pathway. Adagene’s SAFEbody precision masking
technology enables systemic delivery of CTLA-4 treatment similar to
intratumoral delivery to reach a higher concentration at the tumor
site, enabling tumor-specific Treg depletion for effective
immunotherapy.”
In addition to his clinical and translational
research, Professor Marabelle is also the director of the Clinical
Investigation Center BIOTHERIS dedicated to intratumoral
immunotherapies (INSERM CIC1428). He is a full professor of
Clinical Immunology at the University of Paris Saclay. He was
initially trained as a scientist in the Ecole Normale Supérieure de
Lyon and King’s College London and as a clinician at the Léon
Bérard Cancer Center in Lyon, France. He did his post-doctoral
research fellowship in the laboratory of Professor Ronald Levy at
Stanford University on strategies to overcome the resistance to
immune checkpoint targeted therapies. Professor Marabelle is also
an active member of ESMO, ASCO, AACR, SITC, EATI and is the current
President of the French Society for Cancer Immunotherapies (FITC).
He has published more than 250 peer-reviewed publications.
“Professor Aurélien Marabelle pioneered the intratumoral
delivery of anti-CTLA-4 therapy in clinic as a way to overcome the
safety issues of anti-CTLA-4 therapy delivered systemically. This
approach increased the effective concentration of anti-CTLA-4 in
the TME to achieve statistically significant tumor-specific Treg
depletion as a key driver for anti-CTLA-4 therapy, following
Professor Marabelle’s years of preclinical and translation
studies,” said Peter Luo, Ph.D., Co-Founder, Chief Executive
Officer and Chairman of the Board of Adagene. “Reflecting the
vanguard of science at Adagene, we have persistently pursued and
implemented seamless translational studies using the same molecules
targeting the same epitope across different species for our
anti-CTLA-4 programs. We have observed an excellent correlation
from both programs, ADG116 and ADG126, in safety and efficacy both
as single agents and in combination with anti-PD-1 in our ongoing
phase 1b/2 studies. Professor Marabelle’s deep expertise in
translational and biomarker-driven trial design in anti-CTLA-4
therapy will help further strengthen our understanding of
tumor-specific Treg depletion in the development of our novel
anti-CTLA-4 therapies with strong safety and tumor-specific Treg
depletion through systemic delivery.”
For more information about members of the Adagene Scientific and
Strategic Advisory Board, visit:
https://www.adagene.com/about/key-advisors/
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven,
clinical-stage biotechnology company committed to transforming the
discovery and development of novel antibody-based cancer
immunotherapies. Adagene combines computational biology
and artificial intelligence to design novel antibodies that address
unmet patient needs. Powered by its proprietary Dynamic
Precision Library (DPL) platform, composed of NEObody™,
SAFEbody®, and POWERbody™ technologies, Adagene’s highly
differentiated pipeline features novel immunotherapy
programs. Adagene has forged strategic collaborations
with reputable global partners that leverage its technology in
multiple approaches at the vanguard of science.
For more information, please
visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United
States, China, Australia, Japan, Singapore, and
the European Union.
Safe Harbor Statement
This press release contains forward-looking statements,
including statements regarding the potential implications of
clinical data for patients, and Adagene’s advancement of, and
anticipated clinical activities, clinical development, regulatory
milestones, and commercialization of its product candidates. Actual
results may differ materially from those indicated in the
forward-looking statements as a result of various important
factors, including but not limited to Adagene’s ability to
demonstrate the safety and efficacy of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or regulatory approval; the content and timing
of decisions made by the relevant regulatory authorities regarding
regulatory approval of Adagene’s drug candidates; Adagene’s ability
to achieve commercial success for its drug candidates, if approved;
Adagene’s ability to obtain and maintain protection of intellectual
property for its technology and drugs; Adagene’s reliance on third
parties to conduct drug development, manufacturing and other
services; Adagene’s limited operating history and Adagene’s ability
to obtain additional funding for operations and to complete the
development and commercialization of its drug candidates; Adagene’s
ability to enter into additional collaboration agreements beyond
its existing strategic partnerships or collaborations, and the
impact of the COVID-19 pandemic on Adagene’s clinical development,
commercial and other operations, as well as those risks more fully
discussed in the “Risk Factors” section in Adagene’s filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Adagene,
and Adagene undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law.
Investor & Media Contact
Ami Knoefler
650-739-9952
ir@adagene.com
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Mar 2023 to Mar 2024